Seattle Genetics (SGEN) Recorded Record Sales Following Label Expansion; Needham & Company Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Seattle Genetics Reports Third Quarter 2015 Financial Results
October 29, 2015 4:02 PM EDT-Total Third Quarter 2015 Revenues of $84.1 Million, Including Record $59.1 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-ADCETRIS 2015 U.S. and Canada Net Sales Guidance Increased to a Range of $218 Million to $223 Million-
-More than Twenty Presentations at ASH Annual Meeting Featuring Data on ADCETRIS, SGN-CD33A and Other Antibody-Drug Conjugate Pipeline Programs-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)--... More
Seattle Genetics Initiates Phase 2 Clinical Trial of Denintuzumab Mafodotin (SGN-CD19A) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
October 29, 2015 8:01 AM EDT-Trial Based on Data From Phase 1 Trial in B-cell Non-Hodgkin Lymphoma-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) today announced the initiation of a randomized phase 2 clinical trial of denintuzumab mafodotin (SGN-CD19A) in combination with the second-line salvage regimen of rituximab (Rituxan), ifosfamide, carboplatin and etoposide (RICE), for patients... More
Seattle Genetics to Present at Credit Suisse Healthcare Conference
October 28, 2015 8:00 AM EDTBOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that Clay B. Siegall, President and Chief Executive Officer, will present at the Credit Suisse Healthcare... More
